Related Experiment Video

Updated: Feb 18, 2026

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library
07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.3K

Targeting FGFR pathway in breast cancer

J Perez-Garcia1, E Muñoz-Couselo2, J Soberino3

  • 1Baselga Institute of Oncology, Quiron University Hospital, Barcelona, Spain; Medica Scientia Innovation Research (MedSIR), Barcelona, Spain.

Breast (Edinburgh, Scotland)
|November 21, 2017
PubMed

Insights

Targeted therapies for breast cancer are improving patient outcomes. This review covers fibroblast growth factor receptor (FGFR) alterations and inhibitors, highlighting new clinical development opportunities for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Breast cancer subtypes have been molecularly profiled, leading to improved personalized therapies and patient outcomes.
  • Targeted therapies, particularly those inhibiting kinase gene alterations, have transformed cancer treatment.
  • Fibroblast growth factors and their receptors (FGFRs) are crucial in physiological processes and cancer progression.

Purpose of the Study:

  • To summarize molecular alterations of FGFRs in breast cancer.
  • To review preclinical and clinical data on FGFR inhibitors for breast cancer.
  • To discuss future clinical development opportunities for FGFR-targeted agents.

Main Methods:

  • Literature review of preclinical studies.
  • Analysis of clinical trial data for FGFR inhibitors in breast cancer.
  • Synthesis of information on FGFR molecular alterations.

Main Results:

  • FGFRs are implicated in breast cancer cell proliferation, survival, differentiation, migration, and apoptosis.
  • Several FGFR alterations are actionable drug targets.
  • Preclinical and clinical data demonstrate the potential of FGFR inhibitors.

Conclusions:

  • FGFR alterations represent a significant area for targeted breast cancer therapy.
  • FGFR inhibitors show promise for treating specific breast cancer subtypes.
  • Further clinical development of FGFR inhibitors may offer new treatment avenues for breast cancer patients.
Keywords:
Breast cancerFGFR amplificationFibroblast growth factor receptor (FGFR)Multitargeted TKIsSelective FGFR inhibitorsTyrosine kinase inhibitorsTyrosine kinase receptor

More Related Videos

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24